Fiche publication
Date publication
avril 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GANGLOFF Sophie
Tous les auteurs :
Djillani A, Doignon I, Luyten T, Lamkhioued B, Gangloff SC, Parys JB, Nusse O, Chomienne C, Dellis O
Lien Pubmed
Résumé
Store-operated Ca2+ entry (SOCE) is the main Ca2+ entry pathway of non-excitable cells. In the past decade, the activation of this entry has been unveiled, with STIM1, a protein of the endoplasmic reticulum able to sense the intraluminal Ca2+ content, and Orai1, the pore-forming unit of the Ca2+ release activated Ca2+ (CRAC) channels. When Ca2+ ions are released from the endoplasmic reticulum, STIM1 proteins oligomerize and directly interact with Orai1 proteins, allowing the opening of the CRAC channels and a massive Ca2+ ion influx known as SOCE. As Ca2+ is involved in various cellular processes, the discovery of new drugs acting on the SOCE should be of interest to control the cell activity. By testing analogs of 2-aminoethyl diphenylborinate (2-APB), a well known, though not so selective effector of the SOCE, we identified methoxy diethylborinate (MDEB), a molecule able to potentiate the SOCE in three leukocyte and two breast cancer cell lines by increasing the Ca2+ influx amplitude. Unlike 2-APB, MDEB does not affect the Ca2+ pumps or the Ca2+ release from the endoplasmic reticulum. MDEB could therefore represent the first member of a new group of molecules, specifically able to potentiate SOCE. Although not toxic for non-activated Jurkat T cells, it could induce the apoptosis of phytohemagglutinin-stimulated cells.
Référence
Cell Calcium. 2015 Apr 24. pii: S0143-4160(15)00068-8
